Fig. 5: Pretreatment of mice with K4R SHLP2 shows protection in MPTP-lesioned mice.
From: A naturally occurring variant of SHLP2 is a protective factor in Parkinson’s disease
A Schematic diagram of treatment. B Tyrosine hydroxylase (TH) expression in the striatum from mice treated with or without MPTP and WT SHLP2 and K4R variant. (n = 5 per group). C Schematic diagram of treatment. D Dopamine contents were measured by using high-performance liquid chromatography with electrochemical detection in the striatum from mice treated with or without MPTP and WT and K4R SHLP2 (n = 8 per group). Data are reported as mean ± SEM. Significant differences were determined by one-way ANOVA followed by Tukey’s post hoc test *p < 0.05 ** < 0.01**** < 0.0001.
